BACK TO LIVE FEED
● ScienceDeramiocel

FDA Issues Complete Response for Deramiocel

The FDA has rejected Capricor Therapeutics' application for its Duchenne cardiomyopathy therapy, citing significant data integrity failures in clinical trials.

21 Nov 2026SEARCH VOLUME 85
FDA Issues Complete Response for Deramiocel — Deramiocel trending news

Why this is trending right now

On November 21, 2026, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for Deramiocel (CAP-1002), a cell therapy developed by Capricor Therapeutics for Duchenne cardiomyopathy. The agency's refusal to approve the current application stems from “serious clinical trial data integrity deficiencies” identified during Study HOPE-3, which officials determined rendered the clinical data unreliable and incapable of post hoc remediation.

The last 24 hours: a timeline

Throughout the morning of November 21, the healthcare and investment sectors responded to the regulatory setback. Following the official FDA announcement, Parent Project Muscular Dystrophy released a statement highlighting the "devastating" nature of the decision for the Duchenne community. The FDA specified that its rejection was based on a review concluded by November 20, 2026, which found unauthorized changes to the study’s statistical analysis plan and violations of clinical trial blinding procedures. By midday, analysts began assessing the impact of these findings on Capricor’s wider development pipeline, noting that the agency’s concerns specifically target the foundational integrity of the trial data rather than merely secondary efficacy endpoints.

What could happen next

While a CRL signifies that the current application is rejected, it does not permanently bar Deramiocel from future approval. However, the path to a resubmission is narrow. Given the FDA’s assessment that the data is not subject to post hoc remediation, Capricor Therapeutics will likely be required to conduct new, controlled trials to prove the therapy’s efficacy and safety to the agency’s standards. Investors should monitor upcoming disclosures from Capricor regarding their capital reserves and whether they possess the funding to initiate a new Phase 3 study, as the company’s ability to remain solvent through a multi-year trial process remains the primary risk factor.

SOURCES — THE RECORD

24H TRAJECTORY+450%

● THE DAILY DIGEST

Get tomorrow's trends in your inbox

A daily dispatch of the stories shaping global search. Pick the sections you care about.

© 2026 TRENDFRIEND — REAL-TIME TRENDING WORLDWIDE ARTICLES

TrendFriend uses cookies to personalise content, serve ads via Google AdSense, and analyse traffic. By continuing you agree to our use of cookies. Read our cookie policy.